Prevalence of seroprotection against the pandemic (H1N1) virus after the 2009 pandemic

Skowronski, Danuta M.; Hottes, Travis S.; Janjua, Naveed Z.; Purych, Dale; Sabaiduc, Suzana; Chan, Tracy; De Serres, Gaston; Gardy, Jennifer; McElhaney, Janet E.; Patrick, David M.; Petric, Martin
November 2010
CMAJ: Canadian Medical Association Journal;11/23/2010, Vol. 182 Issue 17, p1851
Academic Journal
Background: Before pandemic (H1N1) 2009, less than 10% of serum samples collected from all age groups in the Lower Mainland of British Columbia, Canada, showed seroprotection against the pandemic (H1N1) 2009 virus, except those from very elderly people. We reassessed this profile of seroprotection by age in the same region six months after the fall 2009 pandemic and vaccination campaign. Methods: We evaluated 100 anonymized serum samples per 10-year age group based on convenience sampling. We measured levels of antibody against the pandemic virus by hemagglutination inhibition and microneutralization assays. We assessed geometric mean titres and the proportion of people with seroprotective antibody levels (hemagglutination inhibition titre ≥ 40). We performed sensitivity analyses to evaluate titre thresholds of 80, 20 and 10. Results: Serum samples from 1127 people aged 9 months to 101 years were obtained. The overall age-standardized proportion of people with seroprotective antibody levels was 46%. A U-shaped age distribution was identified regardless of assay or titre threshold applied. Among those less than 20 years old and those 80 years and older, the prevalence of seroprotection was comparably high at about 70%. Seroprotection was 44% among those aged 20-49 and 30% among those 50-79 years. It was lowest among people aged 70-79 years (21%) and highest among those 90 years and older (88%). Interpretation: We measured much higher levels of seroprotection after the 2009 pandemic compared than before the pandemic, with a U-shaped age distribution now evident. These findings, particularly the low levels of seroprotection among people aged 50-79 years, should be confirmed in other settings and closer to the influenza season.


Related Articles

  • Inactivated Seasonal Influenza Vaccines Increase Serum Antibodies to the Neuraminidase of Pandemic Influenza A(H1N1) 2009 Virus in an Age-Dependent Manner. Marcelin, Glendie; Bland, Hilliary M.; Negovetich, Nicholas J.; Sandbulte, Matthew R.; Ellebedy, Ali H.; Webb, Ashley D.; Griffin, Yolanda S.; DeBeauchamp, Jennifer L.; McElhaney, Janet E.; Webby, Richard J. // Journal of Infectious Diseases;12/1/2010, Vol. 202 Issue 11, p1634 

    Levels of preexisting antibodies to the hemagglutinin of pandemic influenza A(H1N1) 2009 (hereafter pandemic H1N1) virus positively correlate with age. The impact of contemporary seasonal influenza vaccines on establishing immunity to other pandemic H1N1 proteins is unknown. We measured serum...

  • Virus-Like Particle Vaccine Protects against 2009 H1N1 Pandemic Influenza Virus in Mice. Fu-Shi Quan; Vunnava, Aswani; Compans, Richard W.; Sang-Moo Kang // PLoS ONE;2010, Vol. 5 Issue 2, p1 

    Background: The 2009 influenza pandemic and shortages in vaccine supplies worldwide underscore the need for new approaches to develop more effective vaccines. Methodology/Principal Findings: We generated influenza virus-like particles (VLPs) containing proteins derived from the A/...

  • H3N2 Influenza Infection Elicits More Cross-Reactive and Less Clonally Expanded Anti-Hemagglutinin Antibodies Than Influenza Vaccination. Moody, M. Anthony; Ruijun Zhang; Walter, Emmanuel B.; Woods, Christopher W.; Ginsburg, Geoffrey S.; McClain, Micah T.; Denny, Thomas N.; Xi Chen; Munshaw, Supriya; Marshall, Dawn J.; Whitesides, John F.; Drinker, Mark S.; Amos, Joshua D.; Gurley, Thaddeus C.; Eudailey, Joshua A.; Foulger, Andrew; DeRosa, Katherine R.; Parks, Robert; Meyerhoff, R. Ryan; Jae-Sung Yu // PLoS ONE;2011, Vol. 6 Issue 10, p1 

    Background: During the recent H1N1 influenza pandemic, excess morbidity and mortality was seen in young but not older adults suggesting that prior infection with influenza strains may have protected older subjects. In contrast, a history of recent seasonal trivalent vaccine in younger adults was...

  • Novel, Real-Time Cell Analysis for Measuring Viral Cytopathogenesis and the Efficacy of Neutralizing Antibodies to the 2009 Influenza A (H1N1) Virus. Di Tian; Wanju Zhang; Jing He; Yi Liu; Zhigang Song; Zhitong Zhou; Min Zheng; Yunwen Hu // PLoS ONE;Feb2012, Vol. 7 Issue 2, p1 

    A novel electronic cell sensor array technology, the real-time cell analysis (RTCA) system, was developed to monitor cell events. Unlike the conventional methods labeling the target cells with fluorescence, luminescence, or light absorption, the RTCA system allows for label-free detection of...

  • MVA-Based H5N1 Vaccine Affords Cross-Clade Protection in Mice against Influenza A/H5N1 Viruses at Low Doses and after Single Immunization.  // PLoS ONE;2009, Vol. 4 Issue 11, p1 

    The article discusses a study which determined the minimal requirements for the induction of protective immunity with modified vaccinia virus Ankara (MVA)-HA-VN/04 against the homologous virus and against an antigenically distinct H5N1 strain. The study found that after a single immunization...

  • Antibody Dynamics of 2009 Influenza A (H1N1) Virus in Infected Patients and Vaccinated People in China. Ming Wang; Jun Yuan; Tiegang Li; Yang Liu; Jibin Wu; Biao Di; Xi Chen; Xinhong Xu; Enjie Lu; Kuibiao Li; Yanhui Liu; Yejian Wu; Xiongfei Chen; Peng He; Yulin Wang; Jianhua Liu // PLoS ONE;2011, Vol. 6 Issue 2, p1 

    Background: To evaluate the risk of the recurrence and the efficiency of the vaccination, we followed-up antibody responses in patients with the 2009 pandemic H1N1 influenza and persons who received the pandemic H1N1 vaccine in Guangzhou China. Methods: We collected serum samples from 129...

  • Immune Protection Induced on Day 10 Following Administration of the 2009 A/H1N1 Pandemic Influenza Vaccine. Yizhuo Sun; Chao Bian; Ke Xu; Weibin Hu; Tongyan Wang; Jun Cui; Hongqiang Wu; Zhiyang Ling; Yongyong Ji; Guomei Lin; Lin Tian; Yanyan Zhou; Bingnan Li; Guiyu Hu; Ning Yu; Wenqi An; Ruowen Pan; Paul Zhou; Qibin Leng; Zhong Huang // PLoS ONE;2010, Vol. 5 Issue 12, p1 

    Background: The 2009 swine-origin influenza virus (S-OIV) H1N1 pandemic has caused more than 18,000 deaths worldwide. Vaccines against the 2009 A/H1N1 influenza virus are useful for preventing infection and controlling the pandemic. The kinetics of the immune response following vaccination with...

  • Swine Influenza A Vaccines, Pandemic (H1N1) 2009 Virus, and Cross-Reactivity. Dürrwald, Ralf; Krumbholz, Andi; Baumgarte, Sigrid; Schlegel, Michael; Vahlenkamp, Thomas W.; Selbitz, Hans-Joachim; Wutzler, Peter; Zell, Roland // Emerging Infectious Diseases;Jun2010, Vol. 16 Issue 6, p1029 

    The article reviews a study which investigated the cross-reactivity of swine influenza A vaccines to pandemic influenza A virus (H1N1). Examination of the hyperimmune serum samples showed neutralizing activity as well as cross-reactivity between the pandemic 2009 virus and European avH1NI...

  • Seroprevalence Following the Second Wave of Pandemic 2009 H1N1 Influenza in Pittsburgh, PA, USA. Zimmer, Shanta M.; Crevar, Corey J.; Carter, Donald M.; Stark, James H.; Giles, Brendan M.; Zimmerman, Richard K.; Ostroff, Stephen M.; Lee, Bruce Y.; Burke, Donald S.; Ross, Ted M. // PLoS ONE;2010, Vol. 5 Issue 7, p1 

    Background: In April 2009, a new pandemic strain of influenza infected thousands of persons in Mexico and the United States and spread rapidly worldwide. During the ensuing summer months, cases ebbed in the Northern Hemisphere while the Southern Hemisphere experienced a typical influenza season...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics